ArticleJournal of the American Geriatrics Society2025
Implementation of Lecanemab for Alzheimer's Disease Within the Veterans Health Administration: Facilitators and Barriers.
Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.The journal of prevention of Alzheimer's disease · 2026Pooled it
- Descriptive Analysis of Retrospective Observational Real-World Evidence of a Monoclonal Anti-Amyloid Therapy Program in a Wide Catchment Specialty Memory Clinic.Neurology and therapy · 2026Article
- Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Implementation of Lecanemab for Alzheimer's Disease Within the Veterans Health Administration: Facilitators and Barriers.Journal of the American Geriatrics Society · 2025Article
- Identifying facility-level and infrastructure-level bottlenecks in Japan's lecanemab rollout through an online survey of dementia specialists.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSeveral amyloid targeting therapies have been approved for Alzheimer's disease (AD), including lecanemab (Leqembi). However, real-world implementation of these drugs has uncovered significant challenges.
methodsWe conducted a national cross-sectional survey of healthcare professionals from multiple disciplines participating in the Veteran's Health Administration (VHA) AD Therapeutics Community of Practice. The goal of the survey was to identify facilitators and barriers to the implementation of lecanemab within their respective medical centers. The web-based survey was open from September 17, 2024 to October 4, 2024.
resultsSurveys were sent to 128 healthcare team members with 44 responders (34% response rate). Of the responders, the majority were physicians (59%, n = 26) or pharmacists (25%, n = 11). In all, 41% indicated that they were currently administering lecanemab (n = 18), 32% were planning on administering lecanemab (n = 14), 20% were unsure if they would be administering lecanemab (n = 9), and 7% did not plan on offering the medication (n = 3). The five most common facilitators to implementation of lecanemab included pharmacist support (57%, n = 25), infusion center access and support (57%, n = 25), having a program champion (43%, n = 19), collaboration with other VHA medical centers implementing lecanemab (43%, n = 19), and access to advanced imaging such as amyloid positron emission tomography (PET) scans (43%, n = 19). The most common barrier to implementation of lecanemab identified by 45% of participants (n = 20) was lack of staff to monitor treatment. Other common barriers included challenges with stakeholder engagement (27%, n = 12), issues with identifying patients who qualify for lecanemab (27%, n = 12), lack of access to advanced imaging (25%, n = 11), and lack of neuroradiology support (23%, n = 10).
conclusionsAttention to identified facilitators and barriers may be helpful for facilities implementing amyloid targeting therapy for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.